UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
ANTX holding history
AN2 Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
ANTX overviewAll 13F holders of ANTXFull Q2 2026 holdings
- Shares (Q2 2026)
- 74,086
- Value
- $358.6K
- % of portfolio
- <0.1%
- Quarters held
- 16
- Since Q1 2022
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 74,086 | $358.6K | <0.1% | +12,694+20.7% | Added | Holders |
| Q1 2026 | 61,392 | $210.0K | <0.1% | +4,724+8.3% | Added | Holders |
| Q4 2025 | 56,668 | $64.6K | <0.1% | −260.0% | Reduced | Holders |
| Q3 2025 | 56,694 | $72.0K | <0.1% | −5,306−8.6% | Reduced | Holders |
| Q2 2025 | 62,000 | $65.7K | <0.1% | −44,021−41.5% | Reduced | Holders |
| Q1 2025 | 106,021 | $144.2K | <0.1% | −64,271−37.7% | Reduced | Holders |
| Q4 2024 | 170,292 | $235.0K | <0.1% | +170,292 | New | Holders |
| Q3 2024 | 0 | $0 | 0.0% | −17,483−100.0% | Sold out | Holders |
| Q2 2024 | 17,483 | $37.6K | <0.1% | −2,091−10.7% | Reduced | Holders |
| Q1 2024 | 19,574 | $63.6K | <0.1% | +19,574 | New | Holders |
| Q4 2023 | 0 | $0 | 0.0% | −41,046−100.0% | Sold out | Holders |
| Q3 2023 | 41,046 | $660.0K | <0.1% | −8,627−17.4% | Reduced | Holders |
| Q2 2023 | 49,673 | $422.2K | <0.1% | −2,552−4.9% | Reduced | Holders |
| Q1 2023 | 52,225 | $515.5K | <0.1% | +770+1.5% | Added | Holders |
| Q4 2022 | 51,455 | $490.4K | <0.1% | +22,348+76.8% | Added | Holders |
| Q3 2022 | 29,107 | $506.0K | <0.1% | −19,260−39.8% | Reduced | Holders |
| Q2 2022 | 48,367 | $375.0K | <0.1% | +47,209+4,076.8% | Added | Holders |
| Q1 2022 | 1,158 | $17.0K | <0.1% | +1,158 | New | Holders |